Drug intelligence / Profile preview

Amnios RT

Development stage: Unknown
Lead developer: DJO Global
Administration: Intralesional, Percutaneous

Overview

Amnios RT is an acellular, liquid tissue allograft derived from human amniotic fluid, designed to promote an environment conducive to healthy tissue regeneration. Manufactured by BoneBank Allografts and distributed by Trilliant Surgical, it contains naturally occurring growth factors and cytokines that help modulate inflammation, reduce fibrosis, and decrease pain. Unlike the standard Amnios product which requires cryopreservation at -70°C, Amnios RT is processed via sterile filtration and low-dose gamma irradiation to allow for ambient temperature storage with a shelf life of one year. It is primarily utilized in surgical applications for tissue repair and is currently being investigated in clinical trials for the treatment of plantar fasciitis.

Brand names: Amnios RT
Other names: Amnios RT Liquid Tissue Allograft

Beyond the preview

Go deeper on Amnios RT.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Amnios RT.

Explore the full profile